Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Shares Purchased by Fmr LLC

Fmr LLC lifted its stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 33.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 115,386 shares of the company’s stock after acquiring an additional 28,773 shares during the quarter. Fmr LLC owned 0.30% of Bolt Biotherapeutics worth $75,000 at the end of the most recent reporting period.

Separately, Acuitas Investments LLC grew its position in Bolt Biotherapeutics by 21.7% in the 2nd quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock valued at $473,000 after acquiring an additional 112,555 shares in the last quarter. 86.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday, November 13th. Five investment analysts have rated the stock with a hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.50.

Bolt Biotherapeutics Stock Performance

Shares of BOLT stock opened at $0.51 on Wednesday. The company has a market cap of $19.63 million, a P/E ratio of -0.30 and a beta of 0.93. The firm has a fifty day moving average price of $0.60 and a 200 day moving average price of $0.66. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21. Bolt Biotherapeutics, Inc. has a 12 month low of $0.48 and a 12 month high of $1.56.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.04). The business had revenue of $1.14 million for the quarter, compared to analyst estimates of $1.02 million. Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. Sell-side analysts predict that Bolt Biotherapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.